Table 2.

Association of investigated SNPs with toxic events

Polymorphism	ABCB1 c.2677 G>T/A	NCF4 c.368G>A	GSTP1 c.313.A>G	CRBN rs1705814 T>C
Hematological toxicity during the induction phase	HoPOL:OR, 0.39 (CI, 0.15-0.88); P = .033	HoPOL/HePOL: OR, 0.56 (CI, 0.34-0.92); P = .024	HoPOL:OR, 0.35 (CI, 0.15-0.79); P = .014
Combined effect		HoWT: OR, 2.26 (CI, 1.09-4.83); P = .031
Infective toxicity	HoPOL: OR, 0.53 (CI, 0.30-0.95) P = .030			HoPOL: OR, 0.39 (CI, 0.22-0.68); P = .001
Lenalidomide dose reduction				HoPOL: OR, 3.24 (CI, 1.69-6.21); P = .013